Department of Ophthalmology, General Hospital of People's Liberation Army, Beijing, China
Department of Ophthalmology, General Hospital of People's Liberation Army, Beijing, China.
Br J Ophthalmol. 2022 Jun;106(6):781-785. doi: 10.1136/bjophthalmol-2019-315617. Epub 2021 Mar 5.
To report the long-term outcomes of Boston keratoprosthesis type I (B-KPro type I) implantation in the management of severe ocular surface disorders.
Retrospective case series. Patients who underwent B-KPro type I implantation at the People's Liberation Army General Hospital were enrolled between March 2011 and September 2019. Data regarding visual acuity (VA), B-KPro type I retention and postoperative complications were recorded and analysed.
A total of 103 eyes of 100 patients who underwent B-KPro type I implantation were included. The main indications were chemical burn (59.2%), ocular trauma (25.2%), herpetic keratitis (11.7%) and autoimmune diseases (3.9%). The percentage of eyes with postoperative VA of 10/200 or better was 82.7% at 6 months, 82.8% at 12 months, 77.9% at 2 years, 72.4% at 3 years, 71.1% at 4 years, 69.4% at 5 years, 58.9% at 6 years, 56.8% at 7 years and 42.9% at 8 years. Preoperatively, 8.7% eyes were diagnosed with new-onset glaucoma. Retroprosthetic membrane formation occurred in 19.4% eye. Corneal melting occurred in 18.4% eyes. Sterile vitritis was diagnosed in 4.9% eyes and infectious endophthalmitis in 2.9% eyes. Retinal detachment occurred in 0.9% eyes.
In a Chinese patient group, B-KPro type I is a viable option for treating severe ocular surface disorders in eyes where conventional keratoplasty would have a poor prognosis, especially in patients with chemical and thermal burns. Improved visual outcomes and high retention rate can be achieved and maintained in most cases.
报告 Boston 角膜型Ⅰ号(B-KPro Ⅰ型)在治疗严重眼表疾病中的长期疗效。
回顾性病例系列研究。2011 年 3 月至 2019 年 9 月,在解放军总医院行 B-KPro Ⅰ型植入术的患者纳入本研究。记录并分析患者的视力(VA)、B-KPro Ⅰ型保留情况和术后并发症等数据。
共纳入 100 例 103 眼行 B-KPro Ⅰ型植入术的患者。主要适应证为化学烧伤(59.2%)、眼外伤(25.2%)、单纯疱疹病毒性角膜炎(11.7%)和自身免疫性疾病(3.9%)。术后 6 个月、12 个月、2 年、3 年、4 年、5 年、6 年、7 年和 8 年时,VA 达 10/200 或以上的眼比例分别为 82.7%、82.8%、77.9%、72.4%、71.1%、69.4%、58.9%、56.8%和 42.9%。术前,8.7%的眼新诊断为开角型青光眼。19.4%的眼发生后弹力层膨出。18.4%的眼发生角膜融解。4.9%的眼诊断为无菌性眼内炎,2.9%的眼诊断为感染性眼内炎。0.9%的眼发生视网膜脱离。
在中国患者人群中,B-KPro Ⅰ型是治疗常规角膜移植预后较差的严重眼表疾病的可行选择,尤其适用于化学性和热烧伤患者。大多数患者可获得并维持良好的视力结果和高 B-KPro Ⅰ型保留率。